Apremilast Therapeutic Cheat Sheet
Apremilast (OTEZLA®) is a twice daily oral medication that is FDA approved for adults with plaque psoriasis, psoriatic arthritis and oral ulcers associated with Behçet’s Disease.1 This drug is being extended as an off-label treatment to target inflammation in a number of different conditions. This Therapeutic Cheat Sheet will focus on apremilast and its applications for different dermatologica …
Apremilast (OTEZLA®) is a twice daily oral medication that is FDA approved for adults with plaque psoriasis, psoriatic arthritis and oral ulcers associated with Behçet’s Disease.1 This drug is being extended as an off-label treatment to target inflammation in a number of different conditions. This Therapeutic Cheat Sheet will focus on apremilast and its applications for different dermatologica … 
Upadacitinib (RINVOQ®) is a once daily oral medication that is FDA approved for a variety of conditions including psoriatic arthritis and atopic dermatitis. Jak inhibitors, like upadacitinib, are a class of drugs showing to be effective in treating inflammatory conditions. Upadacitnib is not only being used to treat rheumatoid arthritis and psoriatic arthritis, but was recently FDA approved i … 
Androgenic alopecia (AGA) is one of the most common forms of hair loss and represents a frequently faced disabling concern in dermatology visits. Targeting the 5α-dihydrotestosterone (DHT) pathway has been shown to be an efficacious mechanism of action, with finasteride being the only systemic FDA-approved drug to treat male AGA. Recently, its sister drug, dutasteride, has been increasingly utili … 
The August issue of the Journal of Drugs in Dermatology (JDD) focuses on Psoriasis and features mix of original articles, editorials, and case reports. Among many of the topics explored in this issue are treatment of scalp psoriasis, nail psoriasis, respiratory tract infections in patients using biologics for hidradenitis suppurativa, classification of actinic keratosis, lichen planus pigmentosus … 
Botulinum toxin is a safe and potentially effective treatment alternative in hidradenitis suppurativa (HS) patients who are resistant to standard therapies, according to the authors of a systematic review published in the Journal of Drugs in Dermatology.
How does this review add to the conversation about new treatments for HS? In which HS patients might dermatologists consider botulinum toxin as … 